Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Interim President & CEO

Chief Scientific Officer

Chief Financial Officer

General Counsel and CCO

President and CEO

EVP, GC, Compliance

Chief Business Officer

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SAR...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Interim President & CEO
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Interim President & CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	General Counsel and CCO
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-02-01	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-02-01	Premium	acquired	Premium	Premium	Premium	EVP, GC, Compliance
2023-02-01	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2023-02-01	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-02-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2021-12-01	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2021-10-18	Premium	acquired	Premium	Premium	Premium	-
2021-02-09	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2020-12-14	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2020-07-23	Premium	sold	Premium	Premium	Premium	Chief Business Officer

ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for ABUS